GCTK

GLUCOTRACK (GCTK) Director Quits, Citing Merger Conflict of Interest

A board member resigned effective immediately, pointing to a potential conflict of interest tied to ongoing discussions over a merger agreement between parent and subsidiary.

INM

INMED (INM) Falls Short of Nasdaq Equity Rule Ahead of Mentari Merger

InMed reported shareholders' equity of $1.08 million, below Nasdaq's $2.5 million minimum, and says its pending merger with Mentari should restore compliance.

HRMY

HARMONY BIOSCIENCES (HRMY) Insider Sells $1.65M in Stock After Option Exercises

A Harmony Biosciences insider exercised 38,452 options at $30.27 and $30.69 and sold the same number of shares at about $43 over three days.

LITE

LUMENTUM (LITE) Insider Yuen Sells 1,500 Shares for About $1.36M

Wupen Yuen sold 500 Lumentum shares on each of three consecutive days at prices between $856.83 and $933.45, leaving 111,627 shares held.

WGS

GENEDX (WGS) CEO Stueland Sells $1.0M in Stock After Option Exercise

GeneDx chief executive Katherine Stueland exercised 18,750 options and sold 10,501 Class A shares at prices between $94.26 and $99.00 on September 16.

AMBA

AMBARELLA (AMBA) CEO and Three Executives Sell $915K in Stock

Four Ambarella insiders, including CEO Feng-Ming Wang and CFO John Young, sold a combined 14,114 shares at $64.83 on the same day.

TEVA

TEVA Posts New SOLARIS Data on Monthly Olanzapine Shot Ahead of FDA Call

Post hoc analysis shows 56% of patients on TEV-'749 reached stabilization, with a PDUFA decision due in the fourth quarter of 2026.

BYSI

BEYONDSPRING (BYSI) Files 8-K on Nasdaq Listing Compliance Issue

The clinical-stage biotech filed an Item 3.01 disclosure covering a delisting notice or failure to meet a continued listing standard.

SOBR

SOBR SAFE Calls Off Clean World Ventures Merger

SOBR Safe and Clean World Ventures mutually terminated their April merger agreement, and the company will withdraw its Form S-4 registration statement.

AMRX

FDA Approves AMNEAL (AMRX) Generic of $983M Somatuline Depot, Launch Immediate

Amneal won FDA approval for lanreotide injection 120 mg/0.5 mL with Competitive Generic Therapy designation and is launching the product immediately.

RETO

RETO ECO-SOLUTIONS Raises $15M in Registered Direct Offering

ReTo Eco-Solutions sold 10 million Class A shares at $1.50 apiece plus warrants that could add up to 90 million shares via a zero-exercise-price option.

Earnings

RESS LIFE INVESTMENTS Posts $6.7M Half-Year Profit Amid Buyer Dispute

The Danish life settlements fund earned USD 6.66 million in the first half of 2026 and flagged a dispute over the sale of most of its policy portfolio.